Loop Capital Lowers Tempus AI (NASDAQ:TEM) Price Target to $52.00

Tempus AI (NASDAQ:TEM) had its price target decreased by investment analysts at Loop Capital from $57.00 to $52.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Loop Capital’s price objective indicates a potential upside of 48.91% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Guggenheim started coverage on shares of Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 target price on the stock. Piper Sandler restated a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Wolfe Research initiated coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Bank of America increased their target price on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research note on Tuesday. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus target price of $56.36.

Tempus AI Price Performance

TEM stock opened at $34.92 on Tuesday. Tempus AI has a 52 week low of $22.89 and a 52 week high of $79.49. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The company’s 50-day simple moving average is $47.24 and its 200 day simple moving average is $47.17.

Insider Activity

In other news, COO Ryan Fukushima sold 120,000 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.51, for a total value of $5,101,200.00. Following the completion of the transaction, the chief operating officer now directly owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. This represents a 10.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 865,041 shares of company stock worth $35,917,673.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Avanza Fonder AB acquired a new stake in Tempus AI during the 4th quarter worth approximately $1,197,000. Bouvel Investment Partners LLC acquired a new position in shares of Tempus AI during the fourth quarter worth $1,029,000. FNY Investment Advisers LLC acquired a new position in shares of Tempus AI during the fourth quarter worth $67,000. Green Alpha Advisors LLC bought a new stake in shares of Tempus AI in the fourth quarter worth $1,090,000. Finally, Silverleafe Capital Partners LLC acquired a new stake in Tempus AI in the fourth quarter valued at $533,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.